Global Central Nervous System Biomarkers Market Size study & Forecast, by Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Others) by Application (Drug Discovery and Development, Personalized Medicine, Other Applications), by End User

Global Central Nervous System Biomarkers Market Size study & Forecast, by Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Others) by Application (Drug Discovery and Development, Personalized Medicine, Other Applications), by End User (Diagnostic Labs, Clinics/Hospitals, Research Centers) and Regional Analysis, 2022-2029

Global Central Nervous System Biomarkers Market is valued approximately at USD 4.19 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.00% over the forecast period 2022-2029. A central nervous system (CNS) biomarker is a measurable substance or characteristic that provides information about the status or function of the central nervous system, which includes the brain and spinal cord. Biomarkers can include molecules such as proteins, metabolites, or genetic markers, as well as imaging or electrophysiological measurements. CNS biomarkers can be used for various purposes, such as diagnosing neurological disorders, monitoring disease progression, evaluating treatment efficacy, or predicting outcomes. The Central Nervous System Biomarkers market is expanding because of factors such as increasing incidences of neurological disorders and increasing research and development with successful clinical trials of biomarkers.

Growing prevelance of neurological disorders across the globe is fostering the market growth. According to report from Alzheimer Disease International Organization, in year 2020, globally there were around 55 million people suffering from dementia and this figure is expected to reach at 78 million in year 2030 and 139 million by year 2050. Additionally, there are more studies in the pipeline to create biomarkers for a variety of diseases, which is anticipated to accelerate the market expansion, For instance in year 2019, The University of Rochester and MC10 Inc. announced their partnership to explore new digital biomarkers for illnesses of the central nervous system. Along with these, increased development in genomics, proteomics, and imaging systems and burgeoning investments from the government and players is creating a lucrative market growth opportunity. However, high Cost of Central Nervous System Biomarkers may hamper the market growth.

The key regions considered for the Global Central Nervous System Biomarkers Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominates the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a fastest CAGR during the forecast period, owing to factors such as rising prevelance of neurological disorders, an increase in the number of collaborations for clinical trial, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Acumen Pharmaceuticals Inc.
Alseres Pharmaceuticals Inc.
vacta Life Sciences Limited
Biomeriux (Banyan Biomarkers Inc.)
Bio-Rad Laboratories Inc.
G-Biosciences
Merck KGaA
Thermo Fisher Scientific Inc.
Eli Lilly and Company (Avid radiopharmaceuticals Inc.)
Proteome Sciences PLC (Service)

Recent Developments in the Market:
In October 2021, Diadem announced the release of clinical data demonstrating that its AlzoSure biomarker test may forecast the course of Alzheimer's disease years before symptoms manifest.
In August 202, Johnson & Johnson Services, Inc. has partnered with Enigma Biomedical Group to research two novel neuroimaging biomarkers, JNJ-64413739 and JNJ-64511070, in an effort to better understand Alzheimer's disease and other dementias.

Global Central Nervous System Biomarkers Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Application, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Safety Biomarkers
Efficacy Biomarkers
Validation Biomarkers
Others

By Application:
Drug Discovery and Development
Personalized Medicine
Other Applications
By End User:
Diagnostic Labs
Clinics/Hospitals
Research Centers

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Acumen Pharmaceuticals Inc.
Alseres Pharmaceuticals Inc.
vacta Life Sciences Limited
Biomeriux (Banyan Biomarkers Inc.)
Bio-Rad Laboratories Inc.
G-Biosciences
Merck KGaA
Thermo Fisher Scientific Inc.
Eli Lilly and Company (Avid radiopharmaceuticals Inc.)
Proteome Sciences PLC (Service)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.